• Development of the cancer protein Ki-67 is discovered in Leipzig, Germany

    In pathology, the protein Ki-67 is used to analyse conspicuous tissue changes. Researchers have discovered how this helpful protein is formed.

  • New study looks into causal link between Epstein-Barr virus and Multiple Sclerosis

    Compelling evidence suggests that many MS cases could be prevented by stopping EBV infection.

  • Second shot COVID-19 vaccine urgently needed for patients treated with immunomodulators

    In 17% of patients with immune-mediated inflammatory diseases (IMID) on immunomodulating treatment, no seroconversion occurred after their first dose of SARS-CoV-2 vaccination.

  • Marked elevation of SII index in psoriasis patients with cardiovascular comorbidity

    The systemic immune-inflammation (SII) index emerged as a novel biomarker associated with a worse prognosis in different diseases.

  • COVID-19 and psoriasis: patients benefit from TNF blockers

    Non-biologic systemic treatment more than doubled the risk for hospitalisation and death compared with tumour necrosis factor (TNF) inhibition.

  • Inhibition of heat shock protein: A novel way to treat psoriasis?

    Inhibition of heat shock protein 90 (HSP90) may be an interesting novel treatment mode for psoriasis. In a proof-of-concept trial, therapy with RGRN-305 showed marked efficacy with an acceptable safety profile.

  • PsA: Upregulation of genes related to neutrophils and monocytes

    Gene profiles for active psoriatic arthritis patients compared with healthy controls showed that genes related to neutrophils, monocytes, eosinophils, and macrophages are upregulated.

  • Guselkumab shows highest drug survival among systemic treatments

    In a comparison of 5 commonly used systemic treatments for psoriasis, guselkumab demonstrated the highest drug survival and adalimumab the lowest at 1 and 2 years.

  • Distinct differences in the microbiota of psoriasis patients

    Psoriasis patients' microbiota are less diverse and have a decreased functional richness compared to healthy controls. Differences occured also in similar lifestyles of psoriasis patients and partners.

  • Tapering biologics: Anti-drug antibodies are not common

    Most healthcare professionals perform dose reductions in psoriasis treatments. A main concern for professionals who do not taper biologics is the formation of anti-drug antibodies.

  • HLA-positive patients treated with ustekinumab show a better drug survival

    A real-world analysis from the BADBIR registry showed that drug survival of ustekinumab, but not from other biologics due to effectiveness, is associated with the psoriasis risk allele HLA-C*06:02.

  • Psoriasis is associated with a higher cancer risk

    A large registry study showed that psoriasis is linked with a higher cancer risk overall and in specific sites, particularly in severe disease. Psoriasis was associated with several cancers beyond those currently regarded as connected.

  • Ixekizumab: confirmed efficacy in psoriatic patients with diabetes

    In a post-hoc investigation of diabetic participants in phase 3 trials, ixekizumab led to high proportions of Psoriasis Area and Severity Index amelioration.

  • DLQI scores: less reliable during the pandemic?

    During the COVID-19 pandemic lockdowns, results of the Dermatology Life Quality Index may have been altered by an increased number of “not-relevant” responses. DLQI-scores could be underestimated.

  • Spesolizumab treatment downregulates IL-36 gene expression in GPP

    Gene expression patterns differed between lesional and non-lesional skin of patients with generalised pustular psoriasis with an upregulation.

  • Fitusiran meets primary endpoint in ATLAS-A/B trial

    Fitusiran prophylactic therapy reduced the ABR in severe haemophilia A or B patients without inhibitors. Quality of life increase was associated with fitusiran therapy.

  • Promising frontline triplet regimen for TP53-mutated AML

    The 5-azacitidine, venetoclax, and magrolimab combo had good response rates in newly diagnosed older, unfit, or TP53-mutated AML patients.

  • rFVIIIFc establishes rapid tolerization in haemophilia A with inhibitors

    rFVIIIFc therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent first ITI therapy.

  • POLARIX: Novel regimen superior to R-CHOP in diffuse large B-cell lymphoma

    Results from the POLARIX trial suggest that Pola-R-CHP may be the preferred first-line therapy for patients with diffuse large B-cell lymphoma.

  • Therapy de-escalation safe in low-risk MRD patients with ALL

    Therapy de-escalation in patients with ALL and a low-risk MRD profile was safe, 10-year follow-up results of the UKALL 2003 trial show.

  • 14 |
  • 15 |
  • 16 |
  • 17 |
  • 18 |
  • 19 |
  • 20 |
  • 21 |
  • 22 |
  • 23 |
  • 24 |